Full text is available at the source.
Abstract
GLP-1 receptor agonists like semaglutide can lead to significant weight loss in patients with obesity.
- Weight loss associated with semaglutide can be substantial.
- Improvement in cardiometabolic risk factors is observed during treatment.
- Most patients experience weight regain after stopping semaglutide.
- The beneficial effects on cardiometabolic health may reverse following withdrawal.
Simplified